P1 gene of Mycoplasma pneumoniae isolated from 2016 to 2019 and relationship between genotyping and macrolide resistance in Hokkaido, Japan

References

1. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev 2017; 30:747–809 [View Article] [PubMed]
   [Google Scholar]
2. Pereyre S, Goret J, Bebear C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 2016; 7:974 [View Article] [PubMed]
   [Google Scholar]
3. Eun BW, Kim NH, Choi EH, Lee HJ. Mycoplasma pneumoniae in Korean children: the epidemiology of pneumonia over an 18-year period. J Infect 2008; 56:326–331 [View Article] [PubMed]
   [Google Scholar]
4. Brown RJ, Nguipdop-Djomo P, Zhao H, Stanford E, Spiller OB et al. Mycoplasma pneumoniae epidemiology in England and wales: a national perspective. Front Microbiol 2016; 7:157 [View Article] [PubMed]
   [Google Scholar]
5. Kubota H, Okuno R, Hatakeyama K, Uchitani Y, Sadamasu K et al. Molecular typing of Mycoplasma pneumoniae isolated from pediatric patients in Tokyo, Japan. Jpn J Infect Dis 2015; 68:76–78 [View Article] [PubMed]
   [Google Scholar]
6. Suzuki Y, Seto J, Itagaki T, Aoki T, Abiko C et al. Gene mutations associated with macrolide-resistance and p1 gene typing of Mycoplasma pneumoniae isolated in Yamagata, Japan, between 2004 and 2013. Kansenshogaku Zasshi 2015; 89:16–22 [View Article] [PubMed]
   [Google Scholar]
7. Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS. Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation. J Clin Microbiol, Evaluation Studies 2008; 46:3116–3118
   [Google Scholar]
8. Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PLoS One 2017; 12:e0173635 [View Article] [PubMed]
   [Google Scholar]
9. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother, Research Support, Non-US Gov’t 2004; 48:4624–4630
   [Google Scholar]
10. Cousin-Allery A, Charron A, de Barbeyrac B, Fremy G, Skov Jensen J et al. Molecular typing of Mycoplasma pneumoniae strains by PCR-based methods and pulsed-field gel electrophoresis. Epidemiol Infect 2000; 124:103–111 [View Article] [PubMed]
    [Google Scholar]
11. Katsukawa C, Kenri T, Shibayama K, Takahashi K. Genetic characterization of Mycoplasma pneumoniae isolated in Osaka between 2011 and 2017: Decreased detection rate of macrolide-resistance and increase of p1 gene type 2 lineage strains. PLoS One 2019; 14:e0209938 [View Article] [PubMed]
    [Google Scholar]
12. Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol 2016; 7:693 [View Article] [PubMed]
    [Google Scholar]
13. Kenri T, Okazaki N, Yamazaki T, Narita M, Izumikawa K et al. Genotyping analysis of Mycoplasma pneumoniae clinical strains in Japan between 1995 and 2005: type shift phenomenon of M. pneumoniae clinical strains. J Med Microbiol, Research Support, Non-US Gov’t 2008; 57:469–475
    [Google Scholar]
14. Ando M, Morozumi M, Adachi Y, Ubukata K, Iwata S. Multilocus sequence typing of Mycoplasma pneumoniae, Japan, 2002–2016. Emerg Infect Dis 2018; 24:1895–1901 [View Article] [PubMed]
    [Google Scholar]